BPC-157 has more marketing than human data. A 2026 systematic review found three human studies with 30 people in total, all uncontrolled and of poor quality, with the certainty of evidence rated very low [2]. FDA's July 2026 review found "insufficient clinical safety information to characterize the safety profile" of BPC-157 [7].
Short answer: nobody knows, because it hasn't been tested properly
Safe means a drug has been given to enough people, for long enough, under controlled conditions, to see what goes wrong. BPC-157 hasn't been. The three uncontrolled reports included in the review reported no treatment-related harm, but their size, follow-up and monitoring cannot establish uncommon or long-term risks [2].
There is a second problem that has nothing to do with the molecule. BPC-157 is not FDA-approved. Absence of approval does not mean absence of all regulation, and an online product is not validated by a seller's quality label [7]. Its full status is on whether BPC-157 is FDA-approved.
The review subtotal: 30 analyzed participants in three reports
The 2026 review searched four databases to June 2026 and found three human studies. One followed knee-pain patients after joint injections (n=16). One followed women with interstitial cystitis after bladder injections (n=12). One tested intravenous safety in two adults (n=2). All reported improvement without treatment-related side effects, and all were judged of poor methodological quality [2].
FDA's review adds older data. Two enema studies from the early 2000s, published only as meeting abstracts, gave BPC-157 to healthy volunteers and to people with ulcerative colitis for up to two weeks. One was placebo-controlled with 53 people, but FDA judged its data inadequate to support either efficacy or safety [7].
| Study | People | Design | Safety finding |
|---|---|---|---|
| Knee injections, retrospective (in Poolton 2026) [2] | 16 | No control group | No treatment-related adverse events reported |
| Lee 2024, bladder injections for interstitial cystitis [4] | 12 women | Single-clinic pilot, no control group | No adverse events reported |
| Lee 2025, intravenous infusion [5] | 2 | Pilot, no control group | No side effects or blood-test changes over three days |
| Enema studies, meeting abstracts (described by FDA) [7] | 24 healthy; 53 randomized with colitis, about 26 assigned active drug | One placebo-controlled; details lacking | Healthy-enema abstracts reported headache and flatulence; colitis abstract had adverse-event withdrawals in both arms; FDA judged safety data inadequate |
Poolton 2026 rated the certainty of evidence very low. A 2025 sports-medicine review found "no clinical safety data" [3].
What FDA flagged in its July 2026 review
FDA's reviewers listed concerns that apply to any BPC-157 product, whoever makes it. The biggest is identity: FDA "has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name" [7]. A patient may get a different substance than the one prescribed or labeled.
- Immune reactions. As an injected or nasal peptide, BPC-157 "may pose a significant risk for immunogenicity", made worse by aggregates and impurities [7].
- Impurities. Storage, concentration and formulation can create peptide impurities and clumps that trigger immune responses [7].
- No route data. FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal administration; this is different from saying no such study was registered [7].
- No long-term data. FDA's reviewed published studies included exposure up to two weeks. A subsequently posted registry describes eight-week gummy use but supplies no results [1] [7].
| Type of study | Found? | Source |
|---|---|---|
| Human absorption data by mouth, under the skin, nasal or on the skin | No | FDA briefing, July 2026 [7] |
| Cancer (carcinogenicity) studies | No | FDA briefing, July 2026 [7] |
| Reproductive and developmental studies by the routes sold | No | FDA briefing, July 2026 [7] |
| Reported eight-week gummy protocol | Registered as completed; no results posted | ClinicalTrials.gov [1] |
Does BPC-157 cause cancer? A dedicated safety gap remains
FDA's July 2026 briefing identified no dedicated carcinogenicity studies [7]. That is an open question, not an answer in either direction. Claims that it is proven cancer-safe or proven to cause cancer are not established by the evidence reviewed here. Mechanistic concern is different from demonstrated clinical causation.
One related result exists. FDA's review cites lab and animal tests in which BPC-157 did not cause gene mutations [7]. Those tests screen for DNA damage. They are not the same as a cancer study, which follows animals over a lifetime of exposure.
Side effects people have reported
FDA searched its adverse-event database (FAERS) through December 2025 and found three reports, all involving injected BPC-157: an injection-site reaction, shortness of breath that led to an emergency visit, and diffuse skin hyperpigmentation with darkening of the gums [7].
FDA says it is unclear whether BPC-157 caused any of them. The first person was also injecting another peptide. The third used a "research purposes only" product that also contained TB-500; the reaction came back when they used it again, but with two peptides in one vial FDA could not tell which was responsible [7]. FDA also notes that 503A compounders generally don't report adverse events to it, so these three reports are not a count of how often problems happen.
FDA also reported three cases from its separate foods and supplements complaint system. Multiple ingredients, other medicines and missing details limited attribution [7]. These are a different reporting search, not a reliable estimate of incidence or proof that BPC-157 alone caused the events. The eight-week gummy registry supplies no safety results [1].
How long BPC-157 stays in the body
In dogs and rats, intravenous BPC-157 had a half-life of 5 to 15 minutes; there are no human data (FDA, 2026, citing He 2022) [7] [6]. FDA's briefing did not establish human pharmacokinetics for the nominated routes [7].
Animal half-lives describe the rate of decline of intact peptide concentration in blood. They say nothing reliable about how long effects last in people, or about drug testing. How oral and injected forms compare is covered in BPC-157 oral vs injection.
Why buying it is itself a safety risk
No FDA-approved BPC-157 drug exists, so the product does not have an approved-drug safety, efficacy and manufacturing assessment. That does not establish whether any particular facility has been inspected or whether an investigational product has separate authorization. "Research use only" products are not intended for people. Add FDA's finding that different molecules are sold under the same name, and the risk starts before the first dose. The distinct rules for ordinary sales and authorized research are explained in BPC-157's legal status for buyers.
| Claim | Where you see it | Human evidence | How much to trust it |
|---|---|---|---|
| "Safe, with no side effects" | Seller and clinic pages | 30 people in uncontrolled studies; three FAERS reports of unclear cause [2] [7] | Low confidence |
| "Heals tendons and ligaments" | Sports and recovery content | No published controlled healing result identified; registered recovery studies have not posted results [2] [3] | Unproven in people |
| "Pharmaceutical grade" | Sellers | No approved drug product; FDA reported multiple substances sold under the name [7] | Unverifiable |
| "Oral is safer" | Capsule sellers | Oral protocols are registered, but the cited records post no results [7] | Unknown |
Who should be especially cautious
BPC-157 is not approved for anyone, so there is no official list of people who should avoid it. These situations carry specific unknowns worth raising with a clinician.
- A personal or family history of cancer. The missing dedicated carcinogenicity assessment is a question to discuss with your treating clinician; this is not a proven family-history contraindication.
- Pregnancy or trying to conceive. FDA "did not identify developmental and reproductive toxicity studies" of BPC-157 delivered by the nominated routes (oral, rectal, under the skin and nasal). An animal study by intramuscular injection exists, but FDA says its results can't be carried over to those routes [7].
- Competitive athletes. WADA prohibits BPC-157 at all times under S0 [8].
Claims about how fast BPC-157 works are a separate question, covered in how long BPC-157 takes to work. How we judge evidence like this is set out on how we check.